02:58 AM EDT, 09/16/2026 (MT Newswires) -- H. Lundbeck (HLUN-A.CO) secured the marketing authorization from Japan's Ministry of Health, Labour and Welfare for its monoclonal antibody Eptinezumab, or Vyepti. The approval will allow the biopharmaceutical company to market Vyepti as a preventive treatment for migraine attacks in adults in Japan, according to a Wednesday release. The company added that the clearance was supported by the results of its phase 3 sunrise and sunset studies.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.